We understand our clients’ critical need to track product usage and treatment drivers on an on-going basis to monitor performance, fine-tune strategy and tactics and for long-term planning. To that end, MDoutlook offers a novel approach to deliver ground-level clinician data and analysis on clinical usage and treatment decision rationale in complex diseases.
Since 2009, MDoutlook has run Physician Treatment Decision panels in melanoma and other diseases. Following recent reporting of the market performance of Yervoy and Taflinar in the US melanoma market, we performed an analysis of the melanoma treatment decisions recorded in the US through our panels and were impressed with the accuracy and relevance of the panel’s reporting.
- Pharma Times On-line reported in July 2013 – “Yervoy second-quarter sales reached $233 million, up 44%”. Our analysis shows that the proportion of new patients receiving Yervoy as 1st line treatment increased by 43% in that same time period (see below).
- First Word– ViewPoints reported in October 2013 – “Early prescription data indicates GlaxoSmithKline’s new melanoma drugs are eroding sales of Roche’s Zelboraf. US prescription data (sourced from Bloomberg) indicates early erosion to Roche’s melanoma treatment Zelboraf at the hands of GlaxoSmithKline’s recently launched therapies Tafinlar and Mekinist. Approved for individual use – but with a supplementary application for combined use pending with the FDA – the data suggests that off-label combination use of GlaxoSmithKline’s drugs may already be occurring frequently.” Our analysis confirms the above and provides much more specific details (see below).
Created by disease, MDoutlook collects clinician-supplied treatment data via syndicated Physician Treatment Decision panels using proprietary technology. Uniquely, our methodology combines insight into the how and why patients are being treated, including rational for each clinical decision. This approach works in the US, Europe and beyond, and runs independent of EMRs to ensure that your specific data needs are fulfilled.
If you want to receive more information on how such insight can support your decision-making, please contact us by email or phone (888.368.8566 / +1.404.496.4136).